Maternal immune activation (MIA) impairs neonatal lung ILC2 establishment, function, and airway hyperresponsiveness

Abstract

Abstract We have recently shown that prenatal inflammation induced by maternal immune activation (MIA) imparts lasting changes to innate immunity by driving the inappropriate expansion and persistence of lymphoid-biased progenitors during fetal life. To test how perturbation during this critical window drives immune dysfunction, we examined underlying changes to lung type-2 innate lymphoid cells (ILC2s) and susceptibility to airway hyperresponsiveness following MIA. MIA induction via a single-low dose injection of poly (I:C) at mid-gestation altered the establishment of a fetal liver (FL) ILC-committed progenitor, increasing cell number and frequency both one- and three-days post MIA. MIA also enhanced lung ILC2 proliferation postnatally, resulting in a robustly expanded ILC2 compartment at postnatal day (P)14 that persisted into adulthood. Concomitant with a greater inflammatory profile, MIA-treated ILC2s were hyperactivated, producing more IL5 and IL13 in-vitro. Lung cytokine levels remained relatively static across early lung development in MIA or saline conditions, suggesting changes to ILC2 proliferation and hyperactivation are cell-intrinsic. Furthermore, hyperactivated ILC2s led to remodeling of the lung immune landscape as observed by expansion of B-, T-, NK-, NKT-cells, alveolar macrophages and eosinophils, but ILC2s were the first immune population to expand in cell number. Altogether, our data suggest MIA imparts lasting changes to lung immunity by perturbing the establishment of committed ILC progenitors in the FL, altering the production of neonatal lung ILC2s poised to hyperactively respond to secondary immune activation, potentially contributing to greater allergic airway hyperresponsiveness. Supported by grants from NIH/NICHD (T32HD007491